(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx, ...

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement signed by both ...

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held biotech IDRx for $1 billion upfront, bringing a rare cancer treatment into ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...

GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

London: GSK plc has announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, ...